Something in the news articles should result in deeper analysis.
The bellow (cut and paste) has been taken from the news.com.au story.
.
Admedus science officer David Rhodes said the primary goal of the new vaccine was not to prevent the spread of herpes simplex but to treat it. “We want to reduce the frequency of the lesions,” he said.
First it was a "therapeutic and prophylactic" vaccine. Then it was just a "therapeutic" vaccine. And now its been refereed to as a "treatment" vaccine.
If the goal is to reduce the frequency of HSV flair ups then the product is like Zovirax for your balls.
Genocea Biosciences and Agenus are managing to reduce "shedding" in one study by 75%.
http://www.fiercevaccines.com/story/agenus-genital-herpes-vax-cuts-viral-load-75-phii/2014-06-27
http://www.webmd.com/sexual-conditi...ug-shows-promise-for-genital-herpes-treatment
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.99 |
Change
-0.150(2.44%) |
Mkt cap ! $92.83M | |||
| Open | High | Low | Value | Volume |
| $6.10 | $6.10 | $5.78 | $105.6K | 17.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $6.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.30 | 100 | 1 |
View Market Depth
| Last trade - 15.55pm 01/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |